首页> 外国专利> Preparing bendamustine alkyl ester compounds, comprises reacting substituted 2-((2-hydroxy-ethyl)-phenyl-amino)-ethanol compounds with a mixture comprising carbonyl amine compounds and sulfonyl compounds, or diketo compounds

Preparing bendamustine alkyl ester compounds, comprises reacting substituted 2-((2-hydroxy-ethyl)-phenyl-amino)-ethanol compounds with a mixture comprising carbonyl amine compounds and sulfonyl compounds, or diketo compounds

机译:制备苯达莫司汀烷基酯化合物,包括使取代的2-(((2-羟基-乙基)-苯基-氨基)-乙醇化合物与包含羰基胺化合物和磺酰基化合物或二酮化合物的混合物反应

摘要

Preparing bendamustine alkyl ester compounds (I) or their salts, comprises reacting substituted 2-[(2-hydroxy-ethyl)-phenyl-amino]-ethanol compounds (III) with a mixture comprising carbonyl amine compounds (IV) and sulfonyl compounds (V), or diketo compounds (VI). Preparing bendamustine alkyl ester compounds of formula (I) or their salts, comprises reacting substituted 2-[(2-hydroxy-ethyl)-phenyl-amino]-ethanol compounds of formula (III) with a mixture comprising carbonyl amine compounds of formula (R6-C(=O)-N(R8)-R7) (IV) and sulfonyl compounds of formula (R9-S(=O)-R10) (V), or diketo compounds of formula (X-C(=O)-C(=O)-X) (VI). X : halo; either R1, R2 : H or CH 2(CH 2) mCOOR3, if R1 is H then R2 is CH 2(CH 2) mCOOR3, or vice versa; or R1R2 : -N=C(CH 2-(CH 2) n-COOR5)-N(R4)-; R3-R5, R7-R10 : alkyl; R6 : H or alkyl; and m, n : 0-12. An independent claim is included for preparing bendamustine compounds of formula (VII) or their salts, comprising preparing (I) by the above process, and undergoing ester hydrolysis of (I). Either R11, R12 : H or CH 2(CH 2) mCOOH, if R11 is H then R12 is CH 2(CH 2) mCOOH, or vice versa; or R11R12 : -N=C(CH 2-(CH 2) n-COOH)-N(R4)-. [Image] [Image] ACTIVITY : Cytostatic. MECHANISM OF ACTION : None given.
机译:制备苯达莫司汀烷基酯化合物(I)或它们的盐,包括将取代的2-[((2-羟基-乙基)-苯基-氨基]-乙醇化合物(III)与包含羰基胺化合物(IV)和磺酰基化合物( V)或二酮化合物(VI)。制备式(I)的苯达莫司汀烷基酯化合物或其盐,包括使式(III)的取代的2-[((2-羟基-乙基)-苯基-氨基]-乙醇)化合物与包含式(I)的羰基胺化合物的混合物反应R6-C(= O)-N(R8)-R7)(IV)和式(R9-S(= O)-R10)(V)的磺酰基化合物或式(XC(= O)- C(= O)-X)(VI)。 X:晕; R1,R2:H或CH 2(CH 2)mCOOR3,如果R1为H,则R2为CH 2(CH 2)mCOOR3,反之亦然;或R1R2:-N = C(CH 2-(CH 2)n-COOR5)-N(R4)-;或R3-R5,R7-R10:烷基; R6:H或烷基; m,n:0-12。包括用于制备式(VII)的苯达莫司汀化合物或其盐的独立权利要求,包括通过上述方法制备(I),并进行(I)的酯水解。 R11,R12:H或CH 2(CH 2)mCOOH,如果R11为H,则R12为CH 2(CH 2)mCOOH,反之亦然;或R 11 R 12:-N = C(CH 2-(CH 2)n -COOH)-N(R 4)-。 [图像] [图像]活动:细胞静止。作用机理:未给出。

著录项

  • 公开/公告号DE102010055499A1

    专利类型

  • 公开/公告日2011-06-16

    原文格式PDF

  • 申请/专利权人 W.C. HERAEUS GMBH;

    申请/专利号DE20101055499

  • 发明设计人 GROH KAI;RAUTER HOLGER;BORN DIRK;

    申请日2010-12-22

  • 分类号C07D235/12;

  • 国家 DE

  • 入库时间 2022-08-21 17:47:08

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号